Immunotherapy of early and late primary Meth A tumors with gp96. Mice with pre-existing tumors of different sizes were treated with gp96 as shown in the left panel. Tumor rejection assays are shown in the other columns comparing tumor diameter (Y-axis) with time (X-axis). Tumor-bearing mice were treated with buffer, Meth A-derived gp96 at 0.5, 1.0 or 5.0 µg/day, or liver-derived gp96 at 0.5 or 1.0 µg/day as indicated. Each line shows the kinetics of tumor growth in a single mouse.